Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion After Progression on Prior Therapies
Conditions
Interventions
BMS-986504
Locations
71
United States
Alaska Oncology and Hematology
Anchorage, Alaska, United States
Local Institution - 0099
Boise, Idaho, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
September 9, 2025
Primary Completion Date
December 29, 2028
Completion Date
December 30, 2031
Last Updated
April 23, 2026
NCT06758401
NCT06120140
NCT04165798
NCT06667908
NCT06875310
NCT07046923
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286Clinical.Trials@bms.comFirst line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions